FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890430658> ?p ?o ?g. }

• W2890430658 endingPage "141" @default.
• W2890430658 startingPage "136" @default.
• W2890430658 abstract "Chemoradiation regimens of greater efficacy are needed for patients with locally advanced non-small cell lung cancer (NSCLC).In a phase I study, escalating doses of weekly nab-paclitaxel (40 or 50 mg/m2) were administered along with weekly carboplatin at an area under the curve (AUC) of 2 mg mL-1 min and concurrent radiotherapy with 60 Gy in 30 fractions to patients with locally advanced NSCLC. This concurrent phase was followed by a consolidation phase consisting of two 3-week cycles of nab-paclitaxel plus carboplatin. In a phase II study, nab-paclitaxel was administered at the recommended dose (RD) together with carboplatin and radiation.In the phase I study, one of six patients experienced dose-limiting toxicity (leukopenia of grade 3 requiring a second consecutive skip in the administration of weekly chemotherapy) with nab-paclitaxel at 50 mg/m2, which was therefore determined to be the RD. Fifty-six patients treated at the RD were evaluable for safety and efficacy. Common toxicities of grade 3 or 4 in the concurrent phase included leukopenia (60.7%) and neutropenia (28.6%). No treatment-related deaths occurred during the study period. The objective response rate was 76.8% (95% confidence interval [CI], 64.2-85.9%), median progression-free survival was 11.8 months (60% CI, 10.6-16.2 months; 95% CI, 8.2-20.8 months), and median overall survival was not reached.Our results reveal encouraging feasibility and activity for concurrent chemoradiation with nab-paclitaxel at 50 mg/m2 and carboplatin at an AUC of 2 in patients with locally advanced NSCLC." @default.
• W2890430658 created "2018-09-27" @default.
• W2890430658 creator A5000467384 @default.
• W2890430658 creator A5001895894 @default.
• W2890430658 creator A5003016795 @default.
• W2890430658 creator A5004891304 @default.
• W2890430658 creator A5034276209 @default.
• W2890430658 creator A5040646045 @default.
• W2890430658 creator A5041714093 @default.
• W2890430658 creator A5045832805 @default.
• W2890430658 creator A5049263315 @default.
• W2890430658 creator A5050825138 @default.
• W2890430658 creator A5054568165 @default.
• W2890430658 creator A5056477482 @default.
• W2890430658 creator A5060336399 @default.
• W2890430658 creator A5065907472 @default.
• W2890430658 creator A5072724155 @default.
• W2890430658 creator A5076225179 @default.
• W2890430658 creator A5086352465 @default.
• W2890430658 creator A5086707100 @default.
• W2890430658 date "2018-11-01" @default.
• W2890430658 modified "2023-10-02" @default.
• W2890430658 title "Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non–small cell lung cancer" @default.
• W2890430658 cites W2017706312 @default.
• W2890430658 cites W2019792640 @default.
• W2890430658 cites W2106787323 @default.
• W2890430658 cites W2107965719 @default.
• W2890430658 cites W2110469369 @default.
• W2890430658 cites W2136240226 @default.
• W2890430658 cites W2144536924 @default.
• W2890430658 cites W2160797118 @default.
• W2890430658 cites W2164067249 @default.
• W2890430658 cites W2566552248 @default.
• W2890430658 cites W2586810147 @default.
• W2890430658 cites W2753065806 @default.
• W2890430658 doi "https://doi.org/10.1016/j.lungcan.2018.09.014" @default.
• W2890430658 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30429011" @default.
• W2890430658 hasPublicationYear "2018" @default.
• W2890430658 type Work @default.
• W2890430658 sameAs 2890430658 @default.
• W2890430658 citedByCount "14" @default.
• W2890430658 countsByYear W28904306582019 @default.
• W2890430658 countsByYear W28904306582020 @default.
• W2890430658 countsByYear W28904306582021 @default.
• W2890430658 countsByYear W28904306582022 @default.
• W2890430658 countsByYear W28904306582023 @default.
• W2890430658 crossrefType "journal-article" @default.
• W2890430658 hasAuthorship W2890430658A5000467384 @default.
• W2890430658 hasAuthorship W2890430658A5001895894 @default.
• W2890430658 hasAuthorship W2890430658A5003016795 @default.
• W2890430658 hasAuthorship W2890430658A5004891304 @default.
• W2890430658 hasAuthorship W2890430658A5034276209 @default.
• W2890430658 hasAuthorship W2890430658A5040646045 @default.
• W2890430658 hasAuthorship W2890430658A5041714093 @default.
• W2890430658 hasAuthorship W2890430658A5045832805 @default.
• W2890430658 hasAuthorship W2890430658A5049263315 @default.
• W2890430658 hasAuthorship W2890430658A5050825138 @default.
• W2890430658 hasAuthorship W2890430658A5054568165 @default.
• W2890430658 hasAuthorship W2890430658A5056477482 @default.
• W2890430658 hasAuthorship W2890430658A5060336399 @default.
• W2890430658 hasAuthorship W2890430658A5065907472 @default.
• W2890430658 hasAuthorship W2890430658A5072724155 @default.
• W2890430658 hasAuthorship W2890430658A5076225179 @default.
• W2890430658 hasAuthorship W2890430658A5086352465 @default.
• W2890430658 hasAuthorship W2890430658A5086707100 @default.
• W2890430658 hasConcept C126322002 @default.
• W2890430658 hasConcept C126894567 @default.
• W2890430658 hasConcept C143998085 @default.
• W2890430658 hasConcept C2776256026 @default.
• W2890430658 hasConcept C2776694085 @default.
• W2890430658 hasConcept C2777063308 @default.
• W2890430658 hasConcept C2777292972 @default.
• W2890430658 hasConcept C2778239845 @default.
• W2890430658 hasConcept C2780873365 @default.
• W2890430658 hasConcept C2781451048 @default.
• W2890430658 hasConcept C31760486 @default.
• W2890430658 hasConcept C509974204 @default.
• W2890430658 hasConcept C71924100 @default.
• W2890430658 hasConcept C90924648 @default.
• W2890430658 hasConceptScore W2890430658C126322002 @default.
• W2890430658 hasConceptScore W2890430658C126894567 @default.
• W2890430658 hasConceptScore W2890430658C143998085 @default.
• W2890430658 hasConceptScore W2890430658C2776256026 @default.
• W2890430658 hasConceptScore W2890430658C2776694085 @default.
• W2890430658 hasConceptScore W2890430658C2777063308 @default.
• W2890430658 hasConceptScore W2890430658C2777292972 @default.
• W2890430658 hasConceptScore W2890430658C2778239845 @default.
• W2890430658 hasConceptScore W2890430658C2780873365 @default.
• W2890430658 hasConceptScore W2890430658C2781451048 @default.
• W2890430658 hasConceptScore W2890430658C31760486 @default.
• W2890430658 hasConceptScore W2890430658C509974204 @default.
• W2890430658 hasConceptScore W2890430658C71924100 @default.
• W2890430658 hasConceptScore W2890430658C90924648 @default.
• W2890430658 hasFunder F4320311653 @default.
• W2890430658 hasLocation W28904306581 @default.
• W2890430658 hasLocation W28904306582 @default.
• W2890430658 hasOpenAccess W2890430658 @default.
• W2890430658 hasPrimaryLocation W28904306581 @default.

• next